Aligned with ASCO's Patient-Centered Oncology Payment model, Anthem has launched its value-based strategy called the oncology medical home, which seeks to promote quality metrics and improve outcome measures in cancer care.
Aligned with the American Society of Clinical Oncology (ASCO)'s Patient-Centered Oncology Payment model, Anthem has launched its value-based strategy, called the oncology medical home, which seeks to promote quality metrics and improve outcome measures in cancer care, said David Debono, MD, medical director of Oncology at Anthem.
Transcript
AJMC®: How has the use of value-based models evolved in cancer care?
Dr Debono: Anthem has recently launched the value-based strategy that we're calling the oncology medical home. The oncology medical home is aligned with ASCO’s Patient-Centered Oncology Payment model. ASCO has gone to great lengths to really provide a guideline for payers and oncology practices on how best to execute value-based strategies.
Their Patient Centered Oncology Payment model centers on 4 components. The first component is what they call practice delivery requirements and we have called our core competencies. These are the type of care processes and comprehensive care that must be available to our members who are receiving oncology care, either within an oncology practice or a cancer center.
The second component of ASCO’s program is participation in a pathways program. We believe that our pathways program, again, is encouraging value-based strategies in oncology and ensuring high-quality care for our members.
The last 2 parts of ASCO’s model revolve around financial incentives for oncology practices. The first is a monthly care coordination fee, and Anthem has designed their monthly care coordination fee to be attributed to those members who are on outpatient chemotherapy or immunotherapy. We believe that the monthly care coordination fee will help support the practice, as they transform their care from a fee-for-service environment to a value-based environment.
The final component of ASCO’s model includes financial incentives for quality care and quality metrics. We have designed financial incentives to be associated with practices improving on quality metrics and improving on outcome measures. We believe that encouraging the improvement of these quality metrics will move the oncology practice toward a higher-value care, without compromising on the exciting modern therapies of precision medicine in oncology.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Frameworks for Advancing Health Equity: Trans and Gender Diverse Health Care
June 28th 2024Charlie Borowicz, manager of trans and gender diverse health at Allegheny Health Network, shares how the program offers comprehensive patient-first care to those in the LGBTQ+ and gender diverse community.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More